Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: TG4001

A randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic(R/M) HPV16-positive cervical or anogenital cancer

C. Le Tourneau, et al. ASCO 2025 Abstract available on the ASCO website – Download the abstract – Download the Poster

Published 22 May 2025
Categorized as -others, 2025, Publication, TG4001, TG4001

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

TG4001 2024

Published 14 October 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release, TG4001, TG4001

Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

Published 29 August 2023
Categorized as -others, 2023, Publication, TG4001, TG4001

Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023

Transgene immunological data demonstrating that TG4001 can induce T-cell responses

Published 5 June 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release, TG4001, TG4001

Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers

C. Le Tourneau, et al. ESMO 2023 Abstract available on the ESMO website – Download the abstract – Download the poster

Published 25 May 2023
Categorized as 2023, Publication, TG4001, TG4001

A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers

C. Le Tourneau, et al. AACR 2023 – Download the Poster

Published 17 April 2023
Categorized as -others, 2023, Publication, TG4001, TG4001

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15

Published 15 March 2023
Categorized as 2023, dates, Press release, TG4001, TG4050, TG6002, TG6050-en

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

TRANSGENE announces positive interim analysis results of Phase II trial evaluating TG4001

Published 2 November 2022
Categorized as 2022, 2022, Press release, dates, Invir.IO, Press release, TG4001, TG4001

R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

TRANSGENE R&D DAY

Published 27 September 2022
Categorized as 2022, Invir.IO, Press release, TG4001, TG4001, TG4050, TG6002

First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers

20210624 Transgene TG4001.12 FPI EN

Published 24 June 2021
Categorized as 2021, Press release, TG4001, TG4001

Posts pagination

Page 1 … Page 3 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu